

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

 ATTORNEY'S DKT
033136-269

 APPLICATION NO.
10/089,362

 APPLICANT
DAVID ELSLEY

 FILING DATE
March 25, 2002

 GROUP
Unassigned 1614

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		

FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no
	2,296,723		Canada (abstract only)	03-11-1999		
	96/34613		WIPO	11-07-1996		
	98/07436		WIPO	02-26-1998		
	99/11260		WIPO	03-11-1999		
	99/13890		WIPO	03-25-1999		
	00/29003		WIPO	05-25-2000		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	ALEGRET, M., et al. "Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits." <i>E. J. Pharmacol.</i> 347: 283-291 (1998).
	BANDOH, T., et al. "Fluvastatin Suppresses Atherosclerotic Progression, Mediated Through Its Inhibitory Effect on Endothelial Dysfunction, Lipid Peroxidation, and Macrophage Deposition." <i>J. Cardio. Pharmacol.</i> 35: 134-144 (2000).
	BOCAN, T.M.A., et al. "Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation." <i>Atherosclerosis.</i> 111: 127-142 (1994).
	DOWELL, F.J., et al. "Development and Progression of Atherosclerosis in Aorta From Heterozygous and Homozygous WHHL Rabbits." <i>Arteriosclerosis, Thrombosis, and Vascular Biology.</i> 15(8): 1152-1160 (1995).
	GAMBHIR, D.S. "Statin Therapy for Prevention of Coronary Artery Disease with Average Cholesterol Levels." <i>Indian Heart J.</i> 51: 19-21 (1999).
	FARNIER, M., et al. "Current and Future Treatment of Hyperlipidemia: The Role of Statins." <i>Am. J. Cardiol.</i> 82(48): 3J-10J (1998).
	KROON, A.A., et al. "The effect of cholesterol reduction on the endothelial function and progression of atherosclerosis in WHHL rabbits." <i>Atherosclerosis.</i> 103(221-230 (1993).
	LAROSA, J.C. "Future Cardiovascular End Point Studies: Where Will the Research Take Us?" <i>Am. J. Cardiol.</i> 84: 454-458 (1999).

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTORNEY'S DKT
033136-269APPLICATION NO.
10/089,362APPLICANT
DAVID ELSLEYFILING DATE
March 25, 2002GROUP
Unassigned 1614

	PEDERSEN, T.R. "Statin trials and goals of cholesterol-lowering therapy after AMI." <i>Am. Heart J.</i> 138: S177-S182 (1999).		
	REYNOLDS, J.E.F. "Martindale, the Extra Pharmacopeia, Thirty-second Edition." London, Royal Pharmaceutical Society. p. 1268-1279. (1994)		
	ROSS, S.D., et al. "Clinical Outcomes in Statin Treatment Trials." <i>Arch. Intern. Med.</i> 159: 1973-1802 (1999).		
	VAUGHAN, C.J., et al. "Neuroprotective Properties of Statins in Cerebral Ischemia and Stroke." <i>Stroke.</i> 30: 1969-1973 (1999).		
	WHEELER, D.C. "Are There Potential Non-Lipid-Lowering Uses of Statins?" <i>Drugs.</i> 5(6): 517-522 (1998).		
Examiner Signature		Date Considered	2/1/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

ATTY DOCKET NO.


559082003600

APPLICATION NO

10/089,362

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



APPLICANT

David ELSLEY

FILING DATE

March 25, 2002

GROUP

1614
~~Not Yet Assigned~~

Sheet 1 of 1

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

1.	Bernini, F., et al. (2001). "Safety of HMG-CoA Reductase Inhibitors: Focus on Atorvastatin," <i>Cardiovascular Drugs and Therapy</i> , 15:211-218.
2.	Blum, C. (1994). "Comparison of Properties of Four Inhibitors of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase," <i>Am. J. Cardio</i> , 73:3D-11D.
3.	"Compendium of Pharmaceuticals and Specialties, 35 th Edition, 2001: The Canadian Reference for Health Professionals," Canadian Pharmacists Association, 815-818, 834-836, 921-923, 1236-1239, 1776-1778.
4.	Hsu, I., et al. (1995). "Comparative Evaluation of the Safety and Efficacy of HMG-CoA Reductase Inhibitor Monotherapy in the Treatment of Primary Hypercholesterolemia," <i>Ann. Of Pharmac.</i> , 29:743-759.
5.	Malhotra, H., et al. (2001). "Atorvastatin: An Updated Review of its Pharmacological Properties and Use in Dyslipidaemia," <i>Adis Drug Evaluation Drugs</i> , (61)12:1835-1881.
6.	Newman, C., et al. (2003). "Safety of Atorvastatin Derived from Analysis of 44 Completed Trials in 9,416 Patients," <i>Am.J.Cardio</i> , 92:670-676.
7.	"Lescol," <i>Physician's Desk Reference</i> , http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/les1221.shtml (2/12/2004).
8.	"Lipitor," <i>Physician's Desk Reference</i> , http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/lip1230.shtml (2/12/2004).
9.	"Mevacor," <i>Physician's Desk Reference</i> , http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/mev1260.shtml (2/12/2004).
10.	"Pravachol," <i>Physician's Desk Reference</i> , http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/prv1344.shtml (2/12/2004).
11.	"Zocor," <i>Physician's Desk Reference</i> , http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/zoc1500.shtml (2/12/2004).

EXAMINER

DATE CONSIDERED

2/1/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.